Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
Rolando Pajón(Moderna Therapeutics (United States)), F. Schödel(St. Marianna University School of Medicine), Bethany Girard(Moderna Therapeutics (United States)), Kathleen M. Mullane(Karolinska University Hospital), Groves Dixon(Moderna Therapeutics (United States)), Edward Kerwin(Clinical Research Institute), Hana M. El Sahly(Baylor College of Medicine), Yamuna Devi Paila(Moderna Therapeutics (United States)), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brett Leav(University of Maryland, Baltimore), Ian Frank(Norwegian Womens Public Health Association), Baoyu Ding(Moderna Therapeutics (United States)), Katherine Kacena, Lindsey R. Baden(Brigham and Women's Hospital), Xiaoping Zhao(Nanyang Technological University), Weiping Deng(Yunnan Agricultural University), Brandon Essink(Velocity Clinical Research (United States)), Douglas Denhan(Clinical Trials of Texas)
Cited by 36
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k